Retatrutide's cardiovascular trial: TRIUMPH-Outcomes is ongoing, enrolling patients with obesity and established cardiovascular disease
All licensed GLP-1 receptor agonists are administered either as subcutaneous injections or, in limited cases, as oral tablets (such as oral semaglutide, marketed as Rybelsus)
The two-receptor mechanism of tirzepatide influences appetite regulation, insulin sensitivity, and energy use through distinct neurological pathways compared to semaglutide's single pathway
However, indirect effects on muscle are possible if significant metabolic disruption occurs during rapid fat loss
But these properties are not sufficient reason to prescribe tirzepatide to someone who would not otherwise be a candidate
How common is nausea after the first GLP-1 injection